Karen Massey

Money Moves

Leading the acquisition and integration

Every medicine argenx sells today reaches patients by infusion or injection. On Nov. 9, 2026, the Dutch immunology company agreed to pay $550 million in cash for a Santa Cruz company whose chemistry is built to make pills instead.

Updated 1 hour ago